The Bio Report

The brain converts short-term memories into long-term memories through the formation and stabilization of new connections between neurons. Tetra Therapeutics is working to treat cognitive impairment and memory loss from Alzheimer’s disease by developing an experimental therapy intended to stabilize these connections. We spoke to Mark Gurney, CEO of Tetra Therapeutics, about memory loss in Alzheimer’s disease, the company’s experimental therapy to treat the condition, and a recent study he was involved in that suggest TNF inhibitors may provide protection against the condition in patients with autoimmune conditions.